1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Alphatec and Theradaptive Forge Strategic Partnership to Advance Regenerative Spine Biologics

15 Jan 2026
Admin
News Article

Alphatec and Theradaptive Forge Strategic Partnership to Advance Regenerative Spine Biologics

Alphatec Holdings (ATEC) and Theradaptive have entered a definitive strategic partnership to bring next-generation regenerative biologics into spine surgery.

The deal gives ATEC exclusive US commercial rights to Theradaptive’s lead bone graft technology, OsteoAdapt, for spinal fusion.

Deal Overview: What Each Company Brings

Under the agreement:

ATEC will market and distribute OsteoAdapt in the US
Theradaptive will receive upfront payments, milestones, and perpetual royalties
The structure is designed for long-term value creation, not one-time upside

This marks one of the most significant regenerative medicine partnerships in the spine industry to date.

About OsteoAdapt: A New Class of Bone Graft

OsteoAdapt is built on Theradaptive’s proprietary AMP2 engineered protein platform.

Key highlights:

Osteoinductive bone graft designed for targeted bone regeneration
Currently in clinical trials for spine and dental indications
Subject to FDA PMA approval
Received three FDA Breakthrough Device Designations

The technology aims to overcome the limitations of traditional allografts and synthetic grafts.

Why This Matters for Spine Surgery?

The spine industry has long lacked biologics that reliably enhance fusion outcomes.

According to ATEC:

Instrumentation and navigation have advanced rapidly
Biologics have not kept pace
Fusion success remains a critical unmet need

OsteoAdapt is positioned to close that gap.

ATEC’s Strategic Rationale

Pat Miles, Chairman and CEO of ATEC, framed the deal as a platform expansion.

Key points:

OsteoAdapt integrates into ATEC’s Organic Innovation Machine
Complements informatics, imaging, navigation, and instrumentation
Designed to raise the bar for clinical distinction in spine surgery

ATEC views biologics as the next lever for procedural differentiation.

Theradaptive Launches Series B Financing

Alongside the partnership, Theradaptive initiated a Series B funding round.

The capital will support:

Completion of the OASIS Pivotal Trial in spinal fusion
Manufacturing scale-up
Commercial readiness aligned with ATEC’s launch strategy

The timing ensures Theradaptive can execute without slowing development.

Market Opportunity: A Large, Underserved Segment

The numbers underscore the strategic logic.

US spine surgery market: $10+ billion annually
Spine biologics segment: $2+ billion
Demand driven by fusion volume and outcome pressure

OsteoAdapt’s targeted approach is intended to disrupt existing graft standards.

Strategic Fit: Why This Partnership Works

Theradaptive gains:

A proven spine-focused commercial partner
Immediate access to a scaled US sales force
Long-term royalty participation

ATEC gains:

A differentiated biologic asset
Control over US commercialization
A potential new category within its ecosystem

Bottom Line

This partnership signals a shift in spine surgery. Instrumentation alone is no longer enough.
The next competitive edge lies in biologics that materially improve fusion outcomes. ATEC and Theradaptive are betting that OsteoAdapt is that inflection point.